|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.421 USD | -0.94% |
|
-24.07% | +49.09% |
IGC Pharma, Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was USD 1.35 million compared to USD 0.911 million a year ago. Net loss was USD 13 million compared to USD 11.51 million a year ago.
Basic loss per share from continuing operations was USD 0.22 compared to USD 0.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +49.09% | 32.15M | |
| +38.65% | 39.1B | |
| -9.33% | 38.76B | |
| +26.82% | 31.24B | |
| +10.72% | 25.9B | |
| -13.50% | 25.8B | |
| +43.56% | 14.06B | |
| +32.89% | 13.12B | |
| -8.41% | 11.32B | |
| -13.42% | 10.68B |
IGC PHARMA, INC. 
